S Suvarna1, R Qi, G M Arepally. 1. Division of Hematology, Duke University Medical Center, Durham, NC 27710, USA.
Abstract
SUMMARY BACKGROUND: Heparin-induced thrombocytopenia (HIT) is a life-threatening thrombotic illness caused by drug-dependent antibodies recognizing complexes of platelet factor 4 (PF4) and heparin. Little is known about the immune pathogenesis of HIT, in particular factors influencing PF4/heparin antibody formation. To gain insight into the biologic basis of heparin sensitization, we have recently developed an animal model using wild-type (WT) mice in which murine PF4/heparin antibodies (anti-mPF4/H) arise de novo after antigen challenge. OBJECTIVES AND METHODS: This report describes technical refinements to the murine model and describes additional biologic features of the immune response to mPF4/heparin. RESULTS: Our studies indicate that antibody responses to mPF4/heparin are dependent on murine strain, injection routes and doses of mPF4 and heparin. C57BL/6 mice are more immunologically responsive to mPF4/heparin antigen than BALB/c mice and robust immunization can be achieved with intravenous, but not intraperitoneal, administration of antigen. We also observe a direct relationship between initial concentrations of mPF4 and antibody levels. Additionally, we demonstrate that mPF4/H immune response in mice decays with time, is not associated with thrombocytopenia and displays characteristics of immune recall on re-exposure to antigen. CONCLUSIONS: These studies describe and characterize a murine model for studying the immunologic basis of PF4/heparin sensitization.
SUMMARY BACKGROUND:Heparin-induced thrombocytopenia (HIT) is a life-threatening thrombotic illness caused by drug-dependent antibodies recognizing complexes of platelet factor 4 (PF4) and heparin. Little is known about the immune pathogenesis of HIT, in particular factors influencing PF4/heparin antibody formation. To gain insight into the biologic basis of heparin sensitization, we have recently developed an animal model using wild-type (WT) mice in which murinePF4/heparin antibodies (anti-mPF4/H) arise de novo after antigen challenge. OBJECTIVES AND METHODS: This report describes technical refinements to the murine model and describes additional biologic features of the immune response to mPF4/heparin. RESULTS: Our studies indicate that antibody responses to mPF4/heparin are dependent on murine strain, injection routes and doses of mPF4 and heparin. C57BL/6 mice are more immunologically responsive to mPF4/heparin antigen than BALB/c mice and robust immunization can be achieved with intravenous, but not intraperitoneal, administration of antigen. We also observe a direct relationship between initial concentrations of mPF4 and antibody levels. Additionally, we demonstrate that mPF4/H immune response in mice decays with time, is not associated with thrombocytopenia and displays characteristics of immune recall on re-exposure to antigen. CONCLUSIONS: These studies describe and characterize a murine model for studying the immunologic basis of PF4/heparin sensitization.
Authors: M P Reilly; S M Taylor; N K Hartman; G M Arepally; B S Sachais; D B Cines; M Poncz; S E McKenzie Journal: Blood Date: 2001-10-15 Impact factor: 22.113
Authors: M V Joglekar; P M Quintana Diez; S Marcus; R Qi; B Espinasse; M R Wiesner; E Pempe; J Liu; D M Monroe; G M Arepally Journal: Thromb Haemost Date: 2012-02-08 Impact factor: 5.249
Authors: Vincent Hayes; Ian Johnston; Gowthami M Arepally; Steven E McKenzie; Douglas B Cines; Lubica Rauova; Mortimer Poncz Journal: J Clin Invest Date: 2017-02-20 Impact factor: 14.808
Authors: Shalini L Chudasama; Benjamin Espinasse; Fred Hwang; Rui Qi; Manali Joglekar; Galyna Afonina; Mark R Wiesner; Ian J Welsby; Thomas L Ortel; Gowthami M Arepally Journal: Blood Date: 2010-09-17 Impact factor: 22.113
Authors: Miriam E Jaax; Krystin Krauel; Thomas Marschall; Sven Brandt; Julia Gansler; Birgitt Fürll; Bettina Appel; Silvia Fischer; Stephan Block; Christiane A Helm; Sabine Müller; Klaus T Preissner; Andreas Greinacher Journal: Blood Date: 2013-05-14 Impact factor: 22.113
Authors: Ernesto Luna; Pankaj Agrawal; Riyaz Mehta; Charlotte Vernhes; Christian Viskov; Jean Amiral; William L Warren; Donald R Drake Journal: Clin Appl Thromb Hemost Date: 2014-12-18 Impact factor: 2.389